Low body weight in females is a risk factor for increased tenofovir exposure and drug-related adverse events
about
Concentrations of Pro-Inflammatory Cytokines Are Not Associated with Senescence Marker p16INK4a or Predictive of Intracellular Emtricitabine/Tenofovir Metabolite and Endogenous Nucleotide Exposures in Adults with HIV InfectionLow Incidence of Renal Dysfunction among HIV-Infected Patients on a Tenofovir-Based First Line Antiretroviral Treatment Regimen in Myanmar.Is Abnormal Urine Protein/Osmolality Ratio Associated with Abnormal Renal Function in Patients Receiving Tenofovir Disoproxil Fumarate?Higher tenofovir exposure is associated with longitudinal declines in kidney function in women living with HIV.Incidence of stage 3 chronic kidney disease and progression on tenofovir-based regimensImpact of obesity on antiretroviral pharmacokinetics and immuno-virological response in HIV-infected patients: a case-control study.Novel Antiretroviral Drugs in Patients with Renal Impairment: Clinical and Pharmacokinetic Considerations.Evaluating the association of single-nucleotide polymorphisms with tenofovir exposure in a diverse prospective cohort of women living with HIV.Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots following Directly Observed Therapy: the DOT-DBS Study.Categorization and association analysis of risk factors for adverse drug events.What do we know about tailoring treatment with tenofovir?
P2860
Q28468505-2B778B05-6148-4F64-9D17-FEB9FB1EA3D2Q35753540-0F94A940-C3DE-44E2-85D0-118B1F10F981Q36576316-5E43BBCB-D248-42FC-8BA3-7E8B610B5EBAQ36663586-C1F7E063-9CD4-4A1C-882D-9DED2C4A7680Q37263602-16AA468B-2CE8-4481-A1E6-B8E7F4F3F9F3Q39033125-DED5E076-C2E1-4EAD-81CD-098CFCC7AF3DQ39074109-08715BC2-B54A-466D-961C-5DD785CC0CE5Q40219167-A82E2AE0-3677-4675-9DEE-9F938A74BEF7Q46323872-0A6A031B-C97F-4613-999C-B78649CE7C3BQ47339342-C55BBF1F-BF0E-4462-B1F7-4728FD6E7AB2Q54624919-18DA349E-155B-4699-B783-7B908EEADCF5
P2860
Low body weight in females is a risk factor for increased tenofovir exposure and drug-related adverse events
description
2013 nî lūn-bûn
@nan
2013 թուականին հրատարակուած գիտական յօդուած
@hyw
2013 թվականին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Low body weight in females is ...... nd drug-related adverse events
@ast
Low body weight in females is ...... nd drug-related adverse events
@en
Low body weight in females is ...... nd drug-related adverse events
@nl
type
label
Low body weight in females is ...... nd drug-related adverse events
@ast
Low body weight in females is ...... nd drug-related adverse events
@en
Low body weight in females is ...... nd drug-related adverse events
@nl
prefLabel
Low body weight in females is ...... nd drug-related adverse events
@ast
Low body weight in females is ...... nd drug-related adverse events
@en
Low body weight in females is ...... nd drug-related adverse events
@nl
P2093
P2860
P50
P1433
P1476
Low body weight in females is ...... nd drug-related adverse events
@en
P2093
Agostino Riva
Cristina Gervasoni
Giuliano Rizzardini
Laura Castagnoli
Sara Baldelli
Serena Fucile
Simona Landonio
P2860
P304
P356
10.1371/JOURNAL.PONE.0080242
P407
P577
2013-01-01T00:00:00Z